Division of Mycobacterial and Respiratory Infections, Department of Medicine, National Jewish Health, Denver, Colorado, USA.
Division of Infectious Diseases, Department of Medicine, University of Colorado, Aurora, Colorado, USA.
Clin Infect Dis. 2024 Oct 15;79(4):e27-e47. doi: 10.1093/cid/ciae421.
Nontuberculous mycobacterial pulmonary disease (NTM-PD) is increasing in incidence globally and challenging to manage. The 2020 multisociety treatment guideline and the 2022 consensus recommendations provide comprehensive evidence-based guides to manage pulmonary diseases caused by the most common NTM. However, with >190 different NTM species that may require different multidrug regimens for treatment, the breadth and complexity of NTM-PD remain daunting for both patients and clinicians. In this narrative review, we aim to distill this broad, complex field into principles applicable to most NTM species and highlight important nuances, specifically elaborating on the presentation, diagnosis, principles of patient-centered care, principles of pathogen-directed therapy, and prospects of NTM-PD.
非结核分枝杆菌肺病(NTM-PD)在全球的发病率不断上升,且难以治疗。2020 年多学会治疗指南和 2022 年共识建议为最常见的 NTM 引起的肺部疾病提供了全面的基于证据的管理指南。然而,由于 >190 种不同的 NTM 物种可能需要不同的多药治疗方案,因此 NTM-PD 的广泛和复杂性对患者和临床医生来说仍然是令人生畏的。在这篇叙述性综述中,我们旨在将这一广泛而复杂的领域提炼为适用于大多数 NTM 物种的原则,并强调重要的细微差别,特别是详细阐述了 NTM-PD 的临床表现、诊断、以患者为中心的护理原则、针对病原体的治疗原则和前景。